# Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease

> **NCT00115427** · PHASE1 · COMPLETED · sponsor: **Amgen**

## Conditions studied

- Idiopathic Parkinson's Disease

## Interventions

- **DRUG:** Liatermin (r-metHuGDNF)

## Key facts

- **NCT ID:** NCT00115427
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115427, "Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00115427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*